RETRACTED ARTICLE: Myricetin nanoliposomes induced SIRT3-mediated glycolytic metabolism leading to glioblastoma cell death
This record is marked as retracted by the source. Review the publisher’s notice before using its findings.
Source abstract
Abstract
As the most aggressive and malignant glioma, glioblastoma multiforme (GBM) abnormally expresses genes that mediate glycolytic metabolism and tumour cell growth. In this study, we investigated myricetin incorporated nanoliposomes and ascertained their prospect in effectively treating cancer via the employment of the GBM cell line DBTRG-05MG. Notably, the myricetin nanoliposomes (MYR-NLs) displayed potent inhibition of proliferation and significantly regulated the levels of proteins related to both glycolytic metabolism and cell survival. Most importantly, SIRT3 and phosphorylated p53 were also down-regulated by MYR-NLs, indicating that the MYR-NLs inhibited GBM cell growth through the SIRT3/p53-mediated PI3K/Akt-ERK and mitochondrial pathways. Our findings thus provide rational evidence that liposomal myricetin targeted at alternative cell death pathways may be a useful adjuvant therapy in glioblastoma treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Sirtuins and Resveratrol in Medicine · Autophagy in Disease and Therapy · Endoplasmic Reticulum Stress and Disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, Shanghai Eighth People's Hospital, Jiangsu University
Department of Medicine, Jiangsu University
Funding
National Natural Science Foundation of China · Shanghai Health Development Planning Commission
References
Reference metadata was not supplied for this record.